Risk factors associated with survival outcomes for lymphoma patients with relapse after anti-CD19 CAR T-cell infusion
| Risk factor . | Hazard ratio HR (95% CI) . |
|---|---|
| • Response to axi-cel | OS: HR 0.45 (95% CI: 0.29-0.71; p = 0.0005)40 |
| • Progression <30 day | OS: HR 2.93 (95% CI: 1.56-5.50; p = 0.0009)37 |
| • CAR T-cell refractoriness | OS: HR 2.33 (95% CI: 1.02-5.29)38 |
| • Grade 3-4 CRS | OS: HR 5.39 (95% CI: 2.48-11.7; p = 2.2. × 10−5)40 |
| • Bridging chemotherapy | OS: HR 2.11 (95% CI: 1.32-3.39; p = 0.002)40 |
| • >2 lines of therapy before CAR T-cell infusion | PFS: HR 1.89 (95% CI: 1.1-3.5; p = 0.03)36 |
| • No double hit or double expressor lymphoma subtype | PFS: HR 0.42 (95% CI: 0.18-0.89; p = 0.03)36 |
| • Polatuzumab-bendamustine-rituximab after CAR T-cell failure as salvage treatment | PFS: HR 0.097 (95% CI: 0.013-0.57; p = 0.01)36 |
| • Lenalidomide-based after CAR T-cell failure as salvage treatment | PFS: HR 0.15, (95% CI: 0.026-0.76; p = 0.03)36 OS: HR 0.42 (95% CI: 0.21.0.82; p = 0.01)37 |
| • High LDH at infusion | PFS: HR 3.42 (95% CI: 1.93-6.05; p < 0.0001) OS: HR 2.10 (95% CI: 1.16-3.78; p = 0.01)37 OS: HR 2.95 (95% CI: 1.61-5.38)38 |
| • High ferritin at infusion | PFS: HR 1.02 (95% CI: 1.00-1.03; p = 0.01)37 |
| • High CRP at infusion | OS: HR 1.11 (95% CI: 1.04-1.19; p = 0.003)37 |
| • Bulky disease at apheresis | OS: HR 2.27 (95% CI: 1.10-4.72)38 |
| • Older age | OS: HR 2.65 (95% CI 1.49-4.73)38 |
| Risk factor . | Hazard ratio HR (95% CI) . |
|---|---|
| • Response to axi-cel | OS: HR 0.45 (95% CI: 0.29-0.71; p = 0.0005)40 |
| • Progression <30 day | OS: HR 2.93 (95% CI: 1.56-5.50; p = 0.0009)37 |
| • CAR T-cell refractoriness | OS: HR 2.33 (95% CI: 1.02-5.29)38 |
| • Grade 3-4 CRS | OS: HR 5.39 (95% CI: 2.48-11.7; p = 2.2. × 10−5)40 |
| • Bridging chemotherapy | OS: HR 2.11 (95% CI: 1.32-3.39; p = 0.002)40 |
| • >2 lines of therapy before CAR T-cell infusion | PFS: HR 1.89 (95% CI: 1.1-3.5; p = 0.03)36 |
| • No double hit or double expressor lymphoma subtype | PFS: HR 0.42 (95% CI: 0.18-0.89; p = 0.03)36 |
| • Polatuzumab-bendamustine-rituximab after CAR T-cell failure as salvage treatment | PFS: HR 0.097 (95% CI: 0.013-0.57; p = 0.01)36 |
| • Lenalidomide-based after CAR T-cell failure as salvage treatment | PFS: HR 0.15, (95% CI: 0.026-0.76; p = 0.03)36 OS: HR 0.42 (95% CI: 0.21.0.82; p = 0.01)37 |
| • High LDH at infusion | PFS: HR 3.42 (95% CI: 1.93-6.05; p < 0.0001) OS: HR 2.10 (95% CI: 1.16-3.78; p = 0.01)37 OS: HR 2.95 (95% CI: 1.61-5.38)38 |
| • High ferritin at infusion | PFS: HR 1.02 (95% CI: 1.00-1.03; p = 0.01)37 |
| • High CRP at infusion | OS: HR 1.11 (95% CI: 1.04-1.19; p = 0.003)37 |
| • Bulky disease at apheresis | OS: HR 2.27 (95% CI: 1.10-4.72)38 |
| • Older age | OS: HR 2.65 (95% CI 1.49-4.73)38 |
CRP, C-reactive protein; CRS, cytokine release syndrome; HR, hazard ratio; LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-free survival.